DISCOUNT ZERTIFIKAT - BOSTON SCIENTIFIC | Real-time Bid/Ask 07:33:07 2024-06-12 am EDT | ||
| 59.17 EUR / 59.52 EUR | +0.01% |
|
| Current month | +1.40% | ||
| 1 month | +1.16% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 59.27 | -0.12% |
| 24-06-11 | 59.34 | +0.17% |
| 24-06-10 | 59.24 | +0.49% |
| 24-06-07 | 58.95 | +0.91% |
| 24-06-06 | 58.42 | -0.24% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 05:46 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME7GY1 |
| ISIN | DE000ME7GY17 |
| Date issued | 2024-01-24 |
| Maturity | 2024-09-20 (101 Days) |
| Parity | 1 : 1 |
| Emission price | 54.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 59.45 € |
|---|---|
| Lowest since issue | 52.88 € |
| Spread | 0.36 € |
| Spread % | 0.60% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77.15
USD
Average target price
82.26
USD
Spread / Average Target
+6.62%
- Stock Market
- Certificates
- Certificat
